The global clinical immunodiagnostics market was valued at US$ 4.8 Billion in 2022 and is expected to reach US$ 8.4 Billion by 2033. The immunoassay kits & reagents segment with a market share of more than 67.0% has topped the global market within the product category and is expected to grow at a CAGR of close to 5.4% over the forecast period (2023 to 2033).
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Clinical Immunodiagnostics Market Value 2022 | US$ 4.8 Billion |
| Market Value 2023 | US$ 5.0 Billion |
| Market Value 2033 | US$ 8.4 Billion |
| CAGR 2023 to 2033 | 5.4% |
| Market Share of Top 5 Countries (2022) | 58.0% |
Clinical immunodiagnostics refers to the diagnostic tests and technologies that utilize immunodiagnostic techniques to detect and measure specific antibodies, antigens, or immune markers in patient samples. Immunodiagnostics involves the interaction between antigens and antibodies, forming an immune complex that is then detected and quantified to provide diagnostic information.
Clinical immunodiagnostics plays a crucial role in diagnosing various diseases and conditions, monitoring treatment efficacy, and assessing immune system function. These tests are commonly used in clinical laboratories, hospitals, and research institutions to identify and measure immune markers associated with infectious diseases, autoimmune disorders, allergies, cancer, and other medical conditions.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market for clinical immunodiagnostics was around 3.7% of the overall US$ 128.2 Billion of the global in vitro diagnostics market in 2022.
The market has experienced significant growth over the years. The increasing prevalence of infectious diseases, autoimmune disorders, and cancer, coupled with advancements in immunodiagnostic technologies, has contributed to the expansion of the market.
The introduction of novel assays improved the sensitivity and specificity of tests, and the adoption of automated platforms has played a key role in the historic growth of the clinical immunodiagnostics market. The global burden of infectious diseases, chronic diseases, and conditions related to the immune system is expected to rise continuously in the coming years.
This will drive the demand for accurate and reliable diagnostic tests, including clinical immunodiagnostics. Also, the need for early disease detection, personalized medicine, and effective monitoring of treatment outcomes will fuel market growth.
Ongoing advancements in immunodiagnostic technologies, such as multiplex assays, high-sensitivity detection methods, and point-of-care testing, are expected to enhance the performance and accessibility of clinical immunodiagnostics. These technological advancements will enable rapid and accurate diagnosis, resulting in increased adoption and market growth.
Owed to the above factors, the global market is projected to grow at a CAGR of 5.4% in the forecasted period.
Clinical Immunodiagnostics are essential in personalized medicine because it helps in facilitating the diagnosis and monitoring of diseases at an individual level. As the demand for personalized treatment options continues to rise, clinical immunodiagnostics product manufacturers have an opportunity to develop innovative assays that enable targeted therapies and precision medicine.
The integration of clinical immunodiagnostics with therapeutics, particularly in oncology, presents opportunities for manufacturers. As targeted therapies become more prevalent, the demand for companion diagnostics is likely to grow. Developing tests that identify patients who will respond positively to specific treatments can enhance the effectiveness of therapies and reduce healthcare costs. Manufacturers can collaborate with pharmaceutical companies to develop companion diagnostic assays that enhance treatment selection and personalized patient care. This would present numerous opportunities for the growth of this market.
Principal Consultant
Clinical immunodiagnostics can involve high costs, including the development and production of assays, instruments, and reagents. The high costs associated with immunodiagnostic tests can limit their accessibility and affordability, particularly in resource-constrained settings or regions with limited healthcare budgets. Cost considerations can impact the demand for clinical immunodiagnostics.
Apart from this, clinical immunodiagnostics faces competition from alternative diagnostic technologies, such as molecular diagnostics, imaging techniques, and other non-immunological assays. These alternative technologies may offer advantages in terms of sensitivity, specificity, multiplexing capabilities, or cost-effectiveness in certain applications. The availability of alternative diagnostic options can limit the demand for clinical immunodiagnostics.
The USA occupies 91.1% of the North America market in 2022. Reimbursement policies play an important role in the adoption of medical technologies. In the USA, favorable reimbursement policies for clinical immunodiagnostics testing have supported market growth. Reimbursement coverage by government programs like Medicare and private insurance companies has incentivized healthcare providers to offer clinical immunodiagnostic-based diagnostics.
Germany’s expenditure in clinical immunodiagnostics in 2022 was US$ 310.6 Million. Personalized medicine, which involves tailoring medical treatment to individual patients based on their genetic profile, is gaining prominence in this region. Germany, known for its strong healthcare and research infrastructure, is actively participating in personalized medicine initiatives. Clinical immunodiagnostics being essential in identifying specific biomarkers for personalized medicine drives the demand for various kits and reagents in the country.
In 2022, China held a significant share of the East Asia market and is expected to grow at a CAGR of close to 6.4% over the forecast period. Chinese clinical immunodiagnostics manufacturers are increasingly collaborating with international companies, leveraging expertise, technologies, and market access. These collaborations help in technology transfer, product development, and expanding the market reach of clinical immunodiagnostics in China. Also, partnerships with healthcare providers and research institutions contribute to the growth of the clinical immunodiagnostics market in China.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By product, immunoassay kits & reagents held 67.8% market share in the world in 2022 and are expected to expand rapidly with a CAGR of 5.4% from 2023 to 2033. Immunoassay kits and reagents have a broad range of applications in clinical immunodiagnostics, covering various disease areas, including infectious diseases, autoimmune disorders, oncology, cardiovascular diseases, and endocrinology. Their versatility and adaptability to different analytes make them essential tools for diagnosing and monitoring a diverse set of medical conditions.
The market value of serum sample type was US$ 1.7 Billion, representing a sizable 35.4% market share in 2022. Serum samples are readily available and routinely used in clinical practice. Healthcare facilities and laboratories can easily collect serum samples from patients for diagnostic testing, making them a convenient and accessible source of biomaterial for immunodiagnostics.
By application, infectious disease accounted for a prominent share of the global market, with a revenue share of 20.7% in 2022. Infectious diseases are widespread and continue to pose a significant global health burden. The high prevalence of infectious diseases, such as influenza, HIV/AIDS, hepatitis, tuberculosis, and various respiratory infections, drives the demand for diagnostic tests based on immunodiagnostics.
With a 26.1% value share in 2022 and a strong CAGR of 6.4% over the projected period, the hospital has a sizable position in this market. Hospitals cater to a large number of patients with diverse medical conditions. As a result, they have a substantial demand for diagnostic testing, including clinical immunodiagnostics. Hospitals frequently utilize immunodiagnostic tests to aid in the diagnosis and inspection of various diseases.
Collaborations with medical professionals, academic institutions, and IT companies can promote creativity and speed up clinical immunodiagnostics. Also, collaboration in research, development, and commercialization can result in new applications and a larger market. The market for clinical immunodiagnostics is dominated by multiple sizable businesses. The important advances of the major companies in this market are illustrated by the following examples:
Similarly, recent developments related to the companies, manufacturing the clinical immunodiagnostics products have been tracked by the team at Future Market Insights, which are available in the full report.
| Report Attributes | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value, Units for Volume |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, France, Spain, BENELUX, Russia, China, Japan, South Korea, India, Indonesia, Thailand, Malaysia, Australia, New Zealand, GCC Countries, Türkiye, South Africa and Northern Africa |
| Key Market Segments Covered | Product, Sample Type, Application, End User, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The clinical immunodiagnostics market size is valued at US$ 5.0 billion in 2023.
The United States occupied 91.1% of the North American clinical immunodiagnostics market share in 2022.
China’s clinical immunodiagnostics market in East Asia rose at a 6.4% CAGR in 2022.
The immunoassay kits & reagents segment will thrive at a 5.4% CAGR from 2023 to 2033.
The infectious disease segment garnered 20.7% of the clinical immunodiagnostics market’s revenue share in 2022.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value-Added Insights
4.1. Product Adoption / Usage Analysis
4.2. Product USPs / features
4.3. Recent Product Approvals and Launches
4.4. Regulatory Scenario, By Country
4.5. PESTLE Analysis
4.6. Porter’s Analysis
4.7. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Industry Market Outlook
5.1.2. Life Science Market Outlook
5.1.3. In Vitro Diagnostics Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Growing Prevalence of Immunological Disorders
5.2.2. Increasing Prevalence of Infectious Diseases
5.2.3. Increased Focus on Personalized Medicine
5.2.4. Growing Investment in Healthcare Expenditures
5.2.5. Technological Advancements
5.2.6. Increasing Number of Immunoassay Kit Manufacturers
5.2.7. Cost of Products
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand in Volume (Units) Analysis 2017 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Volume (Units) Analysis, 2017 to 2022
6.2. Current and Future Market Volume (Units) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
7. Global Market - Pricing Analysis
7.1. Regional Pricing Analysis, By Product
7.2. Global Average Pricing Analysis Benchmark
7.3. Pricing Assumptions
8. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
8.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
8.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
8.2.1. Y-o-Y Growth Trend Analysis
8.2.2. Absolute $ Opportunity Analysis
8.3. Revenue Opportunity Scenario
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Product, 2017 to 2022
9.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Product, 2023 to 2033
9.3.1. Immunoassay Kits & Reagents
9.3.2. Analyzers & Instrument
9.3.3. Software
9.4. Market Attractiveness Analysis, By Product
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Sample Type
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis, By Sample Type, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Sample Type, 2023 to 2033
10.3.1. Serum
10.3.2. Plasma
10.3.3. Urine
10.3.4. Cerebrospinal Fluid
10.3.5. Others
10.4. Market Attractiveness Analysis, By Sample Type
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis, By Application, 2017 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Application, 2023 to 2033
11.3.1. Infectious Disease
11.3.2. Cardiac Disease
11.3.3. Diabetes
11.3.4. Autoimmune Disorders
11.3.5. Inflammatory Maker
11.3.6. Kidney & Liver Disease
11.3.7. Oncology
11.3.8. Others
11.4. Market Attractiveness Analysis, By Application
12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis, By End User, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by End User, 2023 to 2033
12.3.1. Hospital
12.3.2. Specialty Clinics
12.3.3. Academic and Research Institute
12.3.4. Diagnostics Laboratories
12.3.5. Reference Laboratories
12.3.6. Cancer Research Institutes
12.3.7. Veterinary Hospitals
12.3.8. Blood Banks
12.4. Market Attractiveness Analysis, By End User
13. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
13.1. Introduction
13.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Region, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Region, 2023 to 2033
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. East Asia
13.3.5. South Asia
13.3.6. Oceania
13.3.7. Middle East & Africa
13.4. Market Attractiveness Analysis, By Region
14. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) and Volume (Units)Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. USA.
14.3.1.2. Canada
14.3.2. By Product
14.3.3. By Sample Type
14.3.4. By Application
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product
14.4.3. By Sample Type
14.4.4. By Application
14.4.5. By End User
14.5. Drivers and Restraints - Impact Analysis
14.6. Country Level Analysis & Forecast
14.6.1. USA. Market Analysis
14.6.1.1. Introduction
14.6.1.2. Market Analysis and Forecast by Market Taxonomy
14.6.1.2.1. By Product
14.6.1.2.2. By Sample Type
14.6.1.2.3. By Application
14.6.1.2.4. By End User
14.6.2. Canada Market Analysis
14.6.2.1. Introduction
14.6.2.2. Market Analysis and Forecast by Market Taxonomy
14.6.2.2.1. By Product
14.6.2.2.2. By Sample Type
14.6.2.2.3. By Application
14.6.2.2.4. By End User
15. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Volume (Units) and Trend Analysis, By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Mexico
15.3.1.2. Brazil
15.3.1.3. Argentina
15.3.1.4. Rest of Latin America
15.3.2. By Product
15.3.3. By Sample Type
15.3.4. By Application
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Sample Type
15.4.4. By Application
15.4.5. By End User
15.5. Drivers and Restraints - Impact Analysis
15.6. Country Level Analysis & Forecast
15.6.1. Mexico Market Analysis
15.6.1.1. Introduction
15.6.1.2. Market Analysis and Forecast by Market Taxonomy
15.6.1.2.1. By Product
15.6.1.2.2. By Sample Type
15.6.1.2.3. By Application
15.6.1.2.4. By End User
15.6.2. Brazil Market Analysis
15.6.2.1. Introduction
15.6.2.2. Market Analysis and Forecast by Market Taxonomy
15.6.2.2.1. By Product
15.6.2.2.2. By Sample Type
15.6.2.2.3. By Application
15.6.2.2.4. By End User
15.6.3. Argentina Market Analysis
15.6.3.1. Introduction
15.6.3.2. Market Analysis and Forecast by Market Taxonomy
15.6.3.2.1. By Product
15.6.3.2.2. By Sample Type
15.6.3.2.3. By Application
15.6.3.2.4. By End User
16. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. United Kingdom.
16.3.1.2. Germany
16.3.1.3. Italy
16.3.1.4. France
16.3.1.5. Spain
16.3.1.6. Russia
16.3.1.7. BENELUX
16.3.1.8. Rest of Europe
16.3.2. By Product
16.3.3. By Sample Type
16.3.4. By Application
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Sample Type
16.4.4. By Application
16.4.5. By End User
16.5. Drivers and Restraints - Impact Analysis
16.6. Country Level Analysis & Forecast
16.6.1. United Kingdom. Market Analysis
16.6.1.1. Introduction
16.6.1.2. Market Analysis and Forecast by Market Taxonomy
16.6.1.2.1. By Product
16.6.1.2.2. By Sample Type
16.6.1.2.3. By Application
16.6.1.2.4. By End User
16.6.2. Germany Market Analysis
16.6.2.1. Introduction
16.6.2.2. Market Analysis and Forecast by Market Taxonomy
16.6.2.2.1. By Product
16.6.2.2.2. By Sample Type
16.6.2.2.3. By Application
16.6.2.2.4. By End User
16.6.3. Italy Market Analysis
16.6.3.1. Introduction
16.6.3.2. Market Analysis and Forecast by Market Taxonomy
16.6.3.2.1. By Product
16.6.3.2.2. By Sample Type
16.6.3.2.3. By Application
16.6.3.2.4. By End User
16.6.4. France Market Analysis
16.6.4.1. Introduction
16.6.4.2. Market Analysis and Forecast by Market Taxonomy
16.6.4.2.1. By Product
16.6.4.2.2. By Sample Type
16.6.4.2.3. By Application
16.6.4.2.4. By End User
16.6.5. Spain Market Analysis
16.6.5.1. Introduction
16.6.5.2. Market Analysis and Forecast by Market Taxonomy
16.6.5.2.1. By Product
16.6.5.2.2. By Sample Type
16.6.5.2.3. By Application
16.6.5.2.4. By End User
16.6.6. Russia Market Analysis
16.6.6.1. Introduction
16.6.6.2. Market Analysis and Forecast by Market Taxonomy
16.6.6.2.1. By Product
16.6.6.2.2. By Sample Type
16.6.6.2.3. By Application
16.6.6.2.4. By End User
16.6.7. BENELUX Market Analysis
16.6.7.1. Introduction
16.6.7.2. Market Analysis and Forecast by Market Taxonomy
16.6.7.2.1. By Product
16.6.7.2.2. By Sample Type
16.6.7.2.3. By Application
16.6.7.2.4. By End User
17. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Product
17.3.3. By Sample Type
17.3.4. By Application
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Sample Type
17.4.4. By Application
17.4.5. By End User
17.5. Drivers and Restraints - Impact Analysis
17.6. Country Level Analysis & Forecast
17.6.1. China Market Analysis
17.6.1.1. Introduction
17.6.1.2. Market Analysis and Forecast by Market Taxonomy
17.6.1.2.1. By Product
17.6.1.2.2. By Sample Type
17.6.1.2.3. By Application
17.6.1.2.4. By End User
17.6.2. Japan Market Analysis
17.6.2.1. Introduction
17.6.2.2. Market Analysis and Forecast by Market Taxonomy
17.6.2.2.1. By Product
17.6.2.2.2. By Sample Type
17.6.2.2.3. By Application
17.6.2.2.4. By End User
17.6.3. South Korea Market Analysis
17.6.3.1. Introduction
17.6.3.2. Market Analysis and Forecast by Market Taxonomy
17.6.3.2.1. By Product
17.6.3.2.2. By Sample Type
17.6.3.2.3. By Application
17.6.3.2.4. By End User
18. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. India
18.3.1.2. Indonesia
18.3.1.3. Malaysia
18.3.1.4. Thailand
18.3.1.5. Rest of South Asia
18.3.2. By Product
18.3.3. By Sample Type
18.3.4. By Application
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By Sample Type
18.4.4. By Application
18.4.5. By End User
18.5. Drivers and Restraints - Impact Analysis
18.6. Country Level Analysis & Forecast
18.6.1. India Market Analysis
18.6.1.1. Introduction
18.6.1.2. Market Analysis and Forecast by Market Taxonomy
18.6.1.2.1. By Product
18.6.1.2.2. By Sample Type
18.6.1.2.3. By Application
18.6.1.2.4. By End User
18.6.2. Indonesia Market Analysis
18.6.2.1. Introduction
18.6.2.2. Market Analysis and Forecast by Market Taxonomy
18.6.2.2.1. By Product
18.6.2.2.2. By Sample Type
18.6.2.2.3. By Application
18.6.2.2.4. By End User
18.6.3. Malaysia Market Analysis
18.6.3.1. Introduction
18.6.3.2. Market Analysis and Forecast by Market Taxonomy
18.6.3.2.1. By Product
18.6.3.2.2. By Sample Type
18.6.3.2.3. By Application
18.6.3.2.4. By End User
18.6.4. Thailand Market Analysis
18.6.4.1. Introduction
18.6.4.2. Market Analysis and Forecast by Market Taxonomy
18.6.4.2.1. By Product
18.6.4.2.2. By Sample Type
18.6.4.2.3. By Application
18.6.4.2.4. By End User
19. Oceania Market 2017 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022
19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. By Product
19.3.3. By Sample Type
19.3.4. By Application
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Product
19.4.3. By Sample Type
19.4.4. By Application
19.4.5. By End User
19.5. Drivers and Restraints - Impact Analysis
19.6. Country Level Analysis & Forecast
19.6.1. Australia Market Analysis
19.6.1.1. Introduction
19.6.1.2. Market Analysis and Forecast by Market Taxonomy
19.6.1.2.1. By Product
19.6.1.2.2. By Sample Type
19.6.1.2.3. By Application
19.6.1.2.4. By End User
19.6.2. New Zealand Market Analysis
19.6.2.1. Introduction
19.6.2.2. Market Analysis and Forecast by Market Taxonomy
19.6.2.2.1. By Product
19.6.2.2.2. By Sample Type
19.6.2.2.3. By Application
19.6.2.2.4. By End User
20. Middle East & Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2017 to 2022
20.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
20.3.1. By Country
20.3.1.1. GCC Countries
20.3.1.2. Türkiye
20.3.1.3. South Africa
20.3.1.4. Northern Africa
20.3.1.5. Rest of Middle East & Africa
20.3.2. By Product
20.3.3. By Sample Type
20.3.4. By Application
20.3.5. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Product
20.4.3. By Sample Type
20.4.4. By Application
20.4.5. By End User
20.5. Drivers and Restraints - Impact Analysis
20.6. Country Level Analysis & Forecast
20.6.1. GCC Countries Market Analysis
20.6.1.1. Introduction
20.6.1.2. Market Analysis and Forecast by Market Taxonomy
20.6.1.2.1. By Product
20.6.1.2.2. By Sample Type
20.6.1.2.3. By Application
20.6.1.2.4. By End User
20.6.2. Türkiye Market Analysis
20.6.2.1. Introduction
20.6.2.2. Market Analysis and Forecast by Market Taxonomy
20.6.2.2.1. By Product
20.6.2.2.2. By Sample Type
20.6.2.2.3. By Application
20.6.2.2.4. By End User
20.6.3. South Africa Market Analysis
20.6.3.1. Introduction
20.6.3.2. Market Analysis and Forecast by Market Taxonomy
20.6.3.2.1. By Product
20.6.3.2.2. By Sample Type
20.6.3.2.3. By Application
20.6.3.2.4. By End User
20.6.4. Northern Africa Market Analysis
20.6.4.1. Introduction
20.6.4.2. Market Analysis and Forecast by Market Taxonomy
20.6.4.2.1. By Product
20.6.4.2.2. By Sample Type
20.6.4.2.3. By Application
20.6.4.2.4. By End User
21. Market Structure Analysis
21.1. Market Analysis, By Tier of Companies
21.2. Market Share Analysis of Top Players
21.3. Market Presence Analysis
21.3.1. By Regional Footprint of Players
21.3.2. Product Footprint of Players
21.3.3. Channel Footprint of Players
22. Competition Analysis
22.1. Competition Dashboard
22.2. Branding and Promotional Strategies by Key Players
22.3. Key Development Analysis
22.4. Competition Deep Dive
22.4.1. Surmodics, Inc.
22.4.1.1. Overview
22.4.1.2. Product Portfolio
22.4.1.3. Key Financials
22.4.1.4. Sales Footprint
22.4.1.5. Key Developments
22.4.1.6. Strategy Overview
22.4.1.6.1. Marketing Strategy
22.4.1.6.2. Product Strategy
22.4.1.6.3. Channel Strategy
22.4.2. MESO SCALE DIAGNOSTICS, LLC.
22.4.2.1. Overview
22.4.2.2. Product Portfolio
22.4.2.3. Key Financials
22.4.2.4. Sales Footprint
22.4.2.5. Key Developments
22.4.2.6. Strategy Overview
22.4.2.6.1. Marketing Strategy
22.4.2.6.2. Product Strategy
22.4.2.6.3. Channel Strategy
22.4.3. Abbott
22.4.3.1. Overview
22.4.3.2. Product Portfolio
22.4.3.3. Key Financials
22.4.3.4. Sales Footprint
22.4.3.5. Key Developments
22.4.3.6. Strategy Overview
22.4.3.6.1. Marketing Strategy
22.4.3.6.2. Product Strategy
22.4.3.6.3. Channel Strategy
22.4.4. Siemens Healthineers
22.4.4.1. Overview
22.4.4.2. Product Portfolio
22.4.4.3. Key Financials
22.4.4.4. Sales Footprint
22.4.4.5. Key Developments
22.4.4.6. Strategy Overview
22.4.4.6.1. Marketing Strategy
22.4.4.6.2. Product Strategy
22.4.4.6.3. Channel Strategy
22.4.5. PerkinElmer Inc.
22.4.5.1. Overview
22.4.5.2. Product Portfolio
22.4.5.3. Key Financials
22.4.5.4. Sales Footprint
22.4.5.5. Key Developments
22.4.5.6. Strategy Overview
22.4.5.6.1. Marketing Strategy
22.4.5.6.2. Product Strategy
22.4.5.6.3. Channel Strategy
22.4.6. Becton, Dickinson and Company
22.4.6.1. Overview
22.4.6.2. Product Portfolio
22.4.6.3. Key Financials
22.4.6.4. Sales Footprint
22.4.6.5. Key Developments
22.4.6.6. Strategy Overview
22.4.6.6.1. Marketing Strategy
22.4.6.6.2. Product Strategy
22.4.6.6.3. Channel Strategy
22.4.7. Thermo Fisher Scientific Inc.
22.4.7.1. Overview
22.4.7.2. Product Portfolio
22.4.7.3. Key Financials
22.4.7.4. Sales Footprint
22.4.7.5. Key Developments
22.4.7.6. Strategy Overview
22.4.7.6.1. Marketing Strategy
22.4.7.6.2. Product Strategy
22.4.7.6.3. Channel Strategy
22.4.8. Zoetis Inc.
22.4.8.1. Overview
22.4.8.2. Product Portfolio
22.4.8.3. Key Financials
22.4.8.4. Sales Footprint
22.4.8.5. Key Developments
22.4.8.6. Strategy Overview
22.4.8.6.1. Marketing Strategy
22.4.8.6.2. Product Strategy
22.4.8.6.3. Channel Strategy
22.4.9. Promega Corporation
22.4.9.1. Overview
22.4.9.2. Product Portfolio
22.4.9.3. Key Financials
22.4.9.4. Sales Footprint
22.4.9.5. Key Developments
22.4.9.6. Strategy Overview
22.4.9.6.1. Marketing Strategy
22.4.9.6.2. Product Strategy
22.4.9.6.3. Channel Strategy
22.4.10. F. Hoffmann-La Roche
22.4.10.1. Overview
22.4.10.2. Product Portfolio
22.4.10.3. Key Financials
22.4.10.4. Sales Footprint
22.4.10.5. Key Developments
22.4.10.6. Strategy Overview
22.4.10.6.1. Marketing Strategy
22.4.10.6.2. Product Strategy
22.4.10.6.3. Channel Strategy
22.4.11. BIOMÉRIEUX SA
22.4.11.1. Overview
22.4.11.2. Product Portfolio
22.4.11.3. Key Financials
22.4.11.4. Sales Footprint
22.4.11.5. Key Developments
22.4.11.6. Strategy Overview
22.4.11.6.1. Marketing Strategy
22.4.11.6.2. Product Strategy
22.4.11.6.3. Channel Strategy
22.4.12. Elabscience Biotechnology Inc.
22.4.12.1. Overview
22.4.12.2. Product Portfolio
22.4.12.3. Key Financials
22.4.12.4. Sales Footprint
22.4.12.5. Key Developments
22.4.12.6. Strategy Overview
22.4.12.6.1. Marketing Strategy
22.4.12.6.2. Product Strategy
22.4.12.6.3. Channel Strategy
22.4.13. Innovative Research, Inc.
22.4.13.1. Overview
22.4.13.2. Product Portfolio
22.4.13.3. Key Financials
22.4.13.4. Sales Footprint
22.4.13.5. Key Developments
22.4.13.6. Strategy Overview
22.4.13.6.1. Marketing Strategy
22.4.13.6.2. Product Strategy
22.4.13.6.3. Channel Strategy
22.4.14. QIAGEN N.V.
22.4.14.1. Overview
22.4.14.2. Product Portfolio
22.4.14.3. Key Financials
22.4.14.4. Sales Footprint
22.4.14.5. Key Developments
22.4.14.6. Strategy Overview
22.4.14.6.1. Marketing Strategy
22.4.14.6.2. Product Strategy
22.4.14.6.3. Channel Strategy
22.4.15. Merck KGaA
22.4.15.1. Overview
22.4.15.2. Product Portfolio
22.4.15.3. Key Financials
22.4.15.4. Sales Footprint
22.4.15.5. Key Developments
22.4.15.6. Strategy Overview
22.4.15.6.1. Marketing Strategy
22.4.15.6.2. Product Strategy
22.4.15.6.3. Channel Strategy
22.4.16. Bio-Rad Laboratories, Inc.
22.4.16.1. Overview
22.4.16.2. Product Portfolio
22.4.16.3. Key Financials
22.4.16.4. Sales Footprint
22.4.16.5. Key Developments
22.4.16.6. Strategy Overview
22.4.16.6.1. Marketing Strategy
22.4.16.6.2. Product Strategy
22.4.16.6.3. Channel Strategy
22.4.17. Creative Diagnostics
22.4.17.1. Overview
22.4.17.2. Product Portfolio
22.4.17.3. Key Financials
22.4.17.4. Sales Footprint
22.4.17.5. Key Developments
22.4.17.6. Strategy Overview
22.4.17.6.1. Marketing Strategy
22.4.17.6.2. Product Strategy
22.4.17.6.3. Channel Strategy
22.4.18. Cell Signaling Technology (CST)
22.4.18.1. Overview
22.4.18.2. Product Portfolio
22.4.18.3. Key Financials
22.4.18.4. Sales Footprint
22.4.18.5. Key Developments
22.4.18.6. Strategy Overview
22.4.18.6.1. Marketing Strategy
22.4.18.6.2. Product Strategy
22.4.18.6.3. Channel Strategy
22.4.19. NEW HORIZONS DIAGNOSTIC CORPORATION
22.4.19.1. Overview
22.4.19.2. Product Portfolio
22.4.19.3. Key Financials
22.4.19.4. Sales Footprint
22.4.19.5. Key Developments
22.4.19.6. Strategy Overview
22.4.19.6.1. Marketing Strategy
22.4.19.6.2. Product Strategy
22.4.19.6.3. Channel Strategy
22.4.20. DiaSorin S.p.A.
22.4.20.1. Overview
22.4.20.2. Product Portfolio
22.4.20.3. Key Financials
22.4.20.4. Sales Footprint
22.4.20.5. Key Developments
22.4.20.6. Strategy Overview
22.4.20.6.1. Marketing Strategy
22.4.20.6.2. Product Strategy
22.4.20.6.3. Channel Strategy
22.4.21. H.U. Group Holdings Inc
22.4.21.1. Overview
22.4.21.2. Product Portfolio
22.4.21.3. Key Financials
22.4.21.4. Sales Footprint
22.4.21.5. Key Developments
22.4.21.6. Strategy Overview
22.4.21.6.1. Marketing Strategy
22.4.21.6.2. Product Strategy
22.4.21.6.3. Channel Strategy
22.4.22. IDEXX Laboratories Inc.
22.4.22.1. Overview
22.4.22.2. Product Portfolio
22.4.22.3. Key Financials
22.4.22.4. Sales Footprint
22.4.22.5. Key Developments
22.4.22.6. Strategy Overview
22.4.22.6.1. Marketing Strategy
22.4.22.6.2. Product Strategy
22.4.22.6.3. Channel Strategy
22.4.23. Randox Laboratories Ltd.
22.4.23.1. Overview
22.4.23.2. Product Portfolio
22.4.23.3. Key Financials
22.4.23.4. Sales Footprint
22.4.23.5. Key Developments
22.4.23.6. Strategy Overview
22.4.23.6.1. Marketing Strategy
22.4.23.6.2. Product Strategy
22.4.23.6.3. Channel Strategy
22.4.24. Biopanda Reagents Ltd.
22.4.24.1. Overview
22.4.24.2. Product Portfolio
22.4.24.3. Key Financials
22.4.24.4. Sales Footprint
22.4.24.5. Key Developments
22.4.24.6. Strategy Overview
22.4.24.6.1. Marketing Strategy
22.4.24.6.2. Product Strategy
22.4.24.6.3. Channel Strategy
22.4.25. Shenzhen Bioeasy Biotechnology Co., Ltd.
22.4.25.1. Overview
22.4.25.2. Product Portfolio
22.4.25.3. Key Financials
22.4.25.4. Sales Footprint
22.4.25.5. Key Developments
22.4.25.6. Strategy Overview
22.4.25.6.1. Marketing Strategy
22.4.25.6.2. Product Strategy
22.4.25.6.3. Channel Strategy
22.4.26. Quidel Corporation
22.4.26.1. Overview
22.4.26.2. Product Portfolio
22.4.26.3. Key Financials
22.4.26.4. Sales Footprint
22.4.26.5. Key Developments
22.4.26.6. Strategy Overview
22.4.26.6.1. Marketing Strategy
22.4.26.6.2. Product Strategy
22.4.26.6.3. Channel Strategy
22.4.27. Advnt Biotechnologies.
22.4.27.1. Overview
22.4.27.2. Product Portfolio
22.4.27.3. Key Financials
22.4.27.4. Sales Footprint
22.4.27.5. Key Developments
22.4.27.6. Strategy Overview
22.4.27.6.1. Marketing Strategy
22.4.27.6.2. Product Strategy
22.4.27.6.3. Channel Strategy
22.4.28. RESPONSE BIOMEDICAL.
22.4.28.1. Overview
22.4.28.2. Product Portfolio
22.4.28.3. Key Financials
22.4.28.4. Sales Footprint
22.4.28.5. Key Developments
22.4.28.6. Strategy Overview
22.4.28.6.1. Marketing Strategy
22.4.28.6.2. Product Strategy
22.4.28.6.3. Channel Strategy
22.4.29. Danaher Corporation
22.4.29.1. Overview
22.4.29.2. Product Portfolio
22.4.29.3. Key Financials
22.4.29.4. Sales Footprint
22.4.29.5. Key Developments
22.4.29.6. Strategy Overview
22.4.29.6.1. Marketing Strategy
22.4.29.6.2. Product Strategy
22.4.29.6.3. Channel Strategy
23. Assumptions and Acronyms Used
24. Research Methodology
Explore Healthcare Insights
View Reports
Clinical Immunodiagnostics Market
